Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).
Liquid mixtures based on xenon were developed within the framework of the FPI project, which is being carried out in collaboration with the Institute of Cell Biophysics RAS from 2015. The ultimate goal of the project is to create a medicine to extend the “golden hour” by induction of an artificial hypobiosis state in human, similar to the state of hibernation in bears.
“I think that human trials can begin no earlier than three years from now. We have already assessed the effectiveness of the drug, but its safety is not yet assessed,” Mr. Kovtun said.
According to him, it is necessary to go through the entire phase of preclinical studies with testing the drug in no less than four species of animals. Previously, scientists gradually studied the effect of the drug on different groups of animals, starting from small ones: mice, rats, rabbits.
“Now we proceed to the next intermediate experiment on dwarf pigs, which have some physiological parameters that are very similar to humans, especially those of the circulatory system. This is a very reliable object for such intermediate studies. Then we will conduct studies in primates,” commented Mr. Kovtun.